It	PRON	O	O
is	VERB	O	O
recommended	VERB	O	O
that	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
dependence	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
screened	VERB	O	O
for	ADP	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
alterations	NOUN	O	O
in	ADP	O	O
cerebellar	ADJ	O	O
sensory	ADJ	O	O
processing	NOUN	O	O
function	NOUN	O	O
,	PUNCT	O	O
occurring	VERB	O	O
secondary	ADJ	O	O
to	ADP	O	O
abnormal	ADJ	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
signals	NOUN	O	O
reaching	VERB	O	O
it	PRON	O	O
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
important	ADJ	O	O
element	NOUN	O	O
contributing	VERB	O	O
to	ADP	O	O
the	DET	O	O
maladaptive	ADJ	O	O
sensorimotor	NOUN	O	O
plasticity	NOUN	O	O
of	ADP	O	O
M1	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
emergence	NOUN	O	O
of	ADP	O	O
abnormal	ADJ	O	B-Entity
involuntary	ADJ	O	I-Entity
movements	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
behavioral	ADJ	O	O
phenotypes	NOUN	O	O
and	CCONJ	O	O
AChE	PROPN	O	O
activity	NOUN	O	O
in	ADP	O	O
male	ADJ	O	O
mice	NOUN	O	O
following	VERB	O	O
BPA	PROPN	O	I-Entity
exposure	NOUN	O	O
during	ADP	O	O
puberty	NOUN	O	O
.	PUNCT	O	O

Lenalidomide	PROPN	O	I-Entity
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
RD	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
standard	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
for	ADP	O	O
relapsed	VERB	O	O
/	SYM	O	O
refractory	ADJ	O	O
multiple	ADJ	O	B-Entity
myeloma	NOUN	O	I-Entity
(	PUNCT	O	O
RRMM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	ADV	O	O
is	VERB	O	O
limited	VERB	O	O
published	VERB	O	O
data	NOUN	O	O
on	ADP	O	O
its	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
in	ADP	O	O
the	DET	O	O
"	PUNCT	O	O
real	ADJ	O	O
world	NOUN	O	O
"	PUNCT	O	O
(	PUNCT	O	O
RW	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
International	PROPN	O	O
Society	PROPN	O	O
of	ADP	O	O
Pharmacoeconomics	PROPN	O	O
and	CCONJ	O	O
Outcomes	PROPN	O	O
Research	PROPN	O	O
definition	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
its	ADJ	O	O
intense	ADJ	O	O
urotoxic	ADJ	O	O
action	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (23952588)

The	DET	O	O
predictors	NOUN	O	O
of	ADP	O	O
dyskinesia	NOUN	O	I-Entity
were	VERB	O	O
determined	VERB	O	O
using	VERB	O	O
multivariate	NOUN	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
tenofovir	NOUN	O	I-Entity
to	PART	O	O
cause	VERB	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	O
syndromes	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
established	VERB	O	O
from	ADP	O	O
mechanistic	ADJ	O	O
and	CCONJ	O	O
randomised	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

Hodgkin	PROPN	O	B-Entity
lymphoma	NOUN	O	I-Entity
(	PUNCT	O	O
HL	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
relatively	ADV	O	O
chemosensitive	ADJ	O	O
malignancy	NOUN	O	I-Entity
.	PUNCT	O	O

patients	NOUN	O	O
received	VERB	O	O
GEM	PROPN	O	I-Entity
-	PUNCT	O	O
P	PROPN	O	O
as	ADP	O	O
second	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
11/41	NUM	O	O
(	PUNCT	O	O
27	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
Seventy	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
participants	NOUN	O	O
(	PUNCT	O	O
21	NUM	O	O
nonusers	NOUN	O	O
,	PUNCT	O	O
29	NUM	O	O
light	ADJ	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
polydrug	NOUN	O	O
users	NOUN	O	O
,	PUNCT	O	O
26	NUM	O	O
heavy	ADJ	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
polydrug	NOUN	O	O
users	NOUN	O	O
)	PUNCT	O	O
completed	VERB	O	O
a	DET	O	O
substance	NOUN	O	O
use	NOUN	O	O
inventory	NOUN	O	O
and	CCONJ	O	O
measures	NOUN	O	O
of	ADP	O	O
psychological	ADJ	O	O
distress	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
two	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
of	ADP	O	O
cortisol	NOUN	O	I-Entity
sampling	NOUN	O	O
(	PUNCT	O	O
on	ADP	O	O
awakening	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
min	NOUN	O	O
post	NOUN	O	O
awakening	NOUN	O	O
,	PUNCT	O	O
between	ADP	O	O
1400	NUM	O	O
and	CCONJ	O	O
1600	NUM	O	O
hours	NOUN	O	O
and	CCONJ	O	O
pre	VERB	O	O
bedtime	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
user	NOUN	O	O
groups	NOUN	O	O
exhibited	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
anxiety	NOUN	O	I-Entity
and	CCONJ	O	O
depression	NOUN	O	I-Entity
than	ADP	O	O
nonusers	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (24209900)

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
highlight	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
electroencephalogram	NOUN	O	O
(	PUNCT	O	O
EEG	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
detection	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
ifosfamide	ADV	O	I-Entity
related	VERB	O	O
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
her	ADJ	O	O
further	ADJ	O	O
3	NUM	O	O
weeks	NOUN	O	O
inpatient	ADJ	O	O
admission	NOUN	O	O
the	DET	O	O
serum	NOUN	O	O
sodium	NOUN	O	I-Entity
ranged	VERB	O	O
from	ADP	O	O
134	NUM	O	O
to	ADP	O	O
137	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
mirtazapine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DOX)-induced	VERB	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
remains	VERB	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

Glial	ADJ	O	O
activation	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
synaptic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
key	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
Streptozotocin	PROPN	O	I-Entity
(	PUNCT	O	O
ICV	PROPN	O	O
)	PUNCT	O	O
induced	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
apoptotic	ADJ	O	O
marker	NOUN	O	O
,	PUNCT	O	O
synaptic	ADJ	O	O
markers	NOUN	O	O
,	PUNCT	O	O
mitochondrial	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
Ca(2	PROPN	O	I-Entity
+	PUNCT	O	O
)	PUNCT	O	O
levels	NOUN	O	O
remained	VERB	O	O
unaffected	ADJ	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
,	PUNCT	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
and	CCONJ	O	O
isotonic	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
with	ADP	O	O
diltiazem	NOUN	O	I-Entity
application	NOUN	O	O
in	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
CIN	PROPN	O	O
.	PUNCT	O	O

Investigations	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
revealed	VERB	O	O
no	DET	O	O
biochemical	ADJ	O	O
or	CCONJ	O	O
structural	ADJ	O	O
central	ADJ	O	O
nervous	ADJ	O	B-Entity
system	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
that	ADJ	O	O
could	VERB	O	O
have	VERB	O	O
provoked	VERB	O	O
the	DET	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (24438483)

CASE	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
second	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
fluconazole	NOUN	O	I-Entity
associated	VERB	O	O
agranulocytosis	NOUN	O	I-Entity
with	ADP	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
recovery	NOUN	O	O
upon	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Seventy	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
Hodgkin	PROPN	O	I-Entity
lymphoma	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
epirubicin	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
SBP	PROPN	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
H2O2	PROPN	O	I-Entity
level	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
thymus	NOUN	O	O
and	CCONJ	O	O
body	NOUN	O	O
weights	NOUN	O	O
.	PUNCT	O	O

Multivariate	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
identify	VERB	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
describes	VERB	O	O
toxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
protocol	NOUN	O	O
of	ADP	O	O
lomustine	NOUN	O	I-Entity
(	PUNCT	O	O
CCNU	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CTX	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	O
of	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
grade	NOUN	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
(	PUNCT	O	O
19.7	NUM	O	O
kg	NOUN	O	O
+	SYM	O	O
13.4	NUM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
than	ADP	O	O
the	DET	O	O
mean	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	O
of	ADP	O	O
dogs	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
develop	VERB	O	O
grade	NOUN	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
(	PUNCT	O	O
31.7	NUM	O	O
kg	NOUN	O	O
+	SYM	O	O
12.4	NUM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.005	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O


An	DET	O	O
integrated	ADJ	O	O
characterization	NOUN	O	O
of	ADP	O	O
serological	ADJ	O	O
,	PUNCT	O	O
pathological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
functional	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Dexmedetomidine	PROPN	O	I-Entity
and	CCONJ	O	O
propofol	NOUN	O	I-Entity
are	VERB	O	O
commonly	ADV	O	O
used	VERB	O	O
sedatives	NOUN	O	O
in	ADP	O	O
neurocritical	ADJ	O	O
care	NOUN	O	O
as	ADP	O	O
they	PRON	O	O
allow	VERB	O	O
for	ADP	O	O
frequent	ADJ	O	O
neurologic	ADJ	O	O
examinations	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
analyzed	VERB	O	O
separately	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
differences	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
or	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
unmatched	ADJ	O	O
or	CCONJ	O	O
matched	ADJ	O	O
cohorts	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
24	NUM	O	O
hour	NOUN	O	O
excretion	NOUN	O	O
of	ADP	O	O
iodine	NOUN	O	I-Entity
was	VERB	O	O
3657	NUM	O	O
(	PUNCT	O	O
mcg	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
-	SYM	O	O
756	NUM	O	O
(	PUNCT	O	O
mcg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
was	VERB	O	O
transferred	VERB	O	O
to	ADP	O	O
the	DET	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
with	ADP	O	O
cardiopulmonary	ADJ	O	O
compromise	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
superior	ADJ	O	B-Entity
vena	NOUN	O	I-Entity
cava	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
SVC	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
and	CCONJ	O	O
Without	ADP	O	O
Mannitol	PROPN	O	I-Entity
.	PUNCT	O	O

Male	NOUN	O	O
C57BL/6	NOUN	O	O
mice	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
with	ADP	O	O
subconvulsive	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
pentylenetetrazole	NOUN	O	I-Entity
(	PUNCT	O	O
37	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
every	DET	O	O
other	ADJ	O	O
day	NOUN	O	O
for	ADP	O	O
14	NUM	O	O
injections	NOUN	O	O
.	PUNCT	O	O

p53	NOUN	O	O
inhibition	NOUN	O	O
blocked	VERB	O	O
transient	ADJ	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
STAT3	PROPN	O	O
activation	NOUN	O	O
in	ADP	O	O
MHC	PROPN	O	O
-	PUNCT	O	O
CB7	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
enhanced	ADJ	O	O
induction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DNA	PROPN	O	O
repair	NOUN	O	O
proteins	NOUN	O	O
Ku70	PROPN	O	O
and	CCONJ	O	O
Ku80	PROPN	O	O
.	PUNCT	O	O

Aconitine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
bioactive	ADJ	O	O
diterpenoid	NOUN	O	O
alkaloid	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
content	NOUN	O	O
derived	VERB	O	O
from	ADP	O	O
herbal	ADJ	O	O
aconitum	NOUN	O	O
plants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
aconitine	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
and	CCONJ	O	O
reduced	VERB	O	O
NRVMs	PROPN	O	O
viability	NOUN	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
aconitine	NOUN	O	I-Entity
stimulated	VERB	O	O
apoptosis	NOUN	O	O
time	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
.	PUNCT	O	O

Metfromin	PROPN	O	O
markedly	ADV	O	O
lowered	VERB	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
elevation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
TLR4	PROPN	O	O
mRNA	PROPN	O	O
,	PUNCT	O	O
myeloid	ADJ	O	O
differentiation	NOUN	O	O
protein	NOUN	O	O
88	NUM	O	O
(	PUNCT	O	O
MyD88	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
tumor	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
factor	NOUN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
(	PUNCT	O	O
TNF	PROPN	O	O
-	PUNCT	O	O
a	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
interleukin	VERB	O	O
6	NUM	O	O
(	PUNCT	O	O
IL-6	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
tissues	NOUN	O	O
.	PUNCT	O	O

AKI	PROPN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
according	VERB	O	O
to	ADP	O	O
RIFLE	PROPN	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
retrospectively	ADV	O	O
analyzed	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
regimen	NOUN	O	O
of	ADP	O	O
bortezomib	NOUN	O	I-Entity
,	PUNCT	O	O
thalidomide	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
VTD	PROPN	O	O
)	PUNCT	O	O
as	ADP	O	O
consolidation	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
24	NUM	O	O
Japanese	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
MM	PROPN	O	I-Entity
.	PUNCT	O	O

Grade	NOUN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
were	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
four	NUM	O	O
and	CCONJ	O	O
three	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
17	NUM	O	O
and	CCONJ	O	O
13	NUM	O	O
%	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
but	CCONJ	O	O
drug	NOUN	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
cytopenia	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
required	VERB	O	O
in	ADP	O	O
any	DET	O	O
case	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
animal	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
tested	VERB	O	O
during	ADP	O	O
9	NUM	O	O
weeks	NOUN	O	O
:	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
CsA	PROPN	O	I-Entity
,	PUNCT	O	O
SRL	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
conversion	NOUN	O	O
(	PUNCT	O	O
CsA	PROPN	O	I-Entity
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
SRL	PROPN	O	I-Entity
for	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Succinylcholine	PROPN	O	I-Entity
commonly	ADV	O	O
produces	VERB	O	O
frequent	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
muscle	NOUN	O	B-Entity
fasciculation	NOUN	O	I-Entity
and	CCONJ	O	O
myalgia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
particular	ADJ	O	O
case	NOUN	O	O
is	VERB	O	O
of	ADP	O	O
interest	NOUN	O	O
as	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
only	ADV	O	O
occurred	VERB	O	O
after	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	I-Entity
.	PUNCT	O	O


Quetiapine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neutropenia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
bipolar	ADJ	O	I-Entity
patient	NOUN	O	O
with	ADP	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
are	VERB	O	O
some	DET	O	O
case	NOUN	O	O
reports	VERB	O	O
about	ADP	O	O
this	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
quetiapine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
possible	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
are	VERB	O	O
seldom	ADV	O	O
discussed	VERB	O	O
and	CCONJ	O	O
identified	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
observed	VERB	O	O
elevated	ADJ	O	O
lung	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
risks	NOUN	O	O
(	PUNCT	O	O
N=283	PROPN	O	O
)	PUNCT	O	O
among	ADP	O	O
applicators	NOUN	O	O
with	ADP	O	O
the	DET	O	O
greatest	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
LT	PROPN	O	O
(	PUNCT	O	O
RR=1.60	PROPN	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.11	NUM	O	O
to	ADP	O	O
2.31	NUM	O	O
;	PUNCT	O	O
Ptrend=0.02	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
IW	PROPN	O	O
days	NOUN	O	O
of	ADP	O	O
diazinon	NOUN	O	I-Entity
use	NOUN	O	O
(	PUNCT	O	O
RR=1.41	PROPN	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.98	NUM	O	O
to	ADP	O	O
2.04	NUM	O	O
;	PUNCT	O	O
Ptrend=0.08	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O


The	DET	O	O
compound	NOUN	O	O
P11	PROPN	O	I-Entity
is	VERB	O	O
introduced	VERB	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
0.25	NUM	O	O
and	CCONJ	O	O
0.50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
intravenously	ADV	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
orally	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
six	NUM	O	O
dogs	NOUN	O	O
with	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
VIP	PROPN	O	O
decreased	VERB	O	O
from	ADP	O	O
31	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
other	ADJ	O	O
animals	NOUN	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
15	NUM	O	O
or	CCONJ	O	O
60	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
caffeine	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
any	DET	O	O
single	ADJ	O	O
behavioral	ADJ	O	O
criterion	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
these	DET	O	O
criteria	NOUN	O	O
,	PUNCT	O	O
marked	VERB	O	O
differences	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
toxic	ADJ	O	O
caffeine	NOUN	O	I-Entity
doses	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
strains	NOUN	O	O
.	PUNCT	O	O

Invasive	ADJ	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
renal	ADJ	O	I-Entity
pelvis	NOUN	O	I-Entity
following	VERB	O	O
cyclophosphamide	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
nonmalignant	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Ascending	VERB	O	O
dose	NOUN	O	O
tolerance	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
intramuscular	NOUN	O	O
carbetocin	NOUN	O	I-Entity
administered	VERB	O	O
after	ADP	O	O
normal	ADJ	O	O
vaginal	ADJ	O	O
birth	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (11423811)

We	PRON	O	O
report	VERB	O	O
4	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
corneal	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
drug	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
corneal	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
were	VERB	O	O
cultured	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
for	ADP	O	O
intensive	ADJ	O	O
topical	ADJ	O	O
antibiotic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


BACKGROUND	PROPN	O	O
AND	CCONJ	O	O
PURPOSE	PROPN	O	O
:	PUNCT	O	O
Cerebral	ADJ	O	B-Entity
microbleeds	NOUN	O	I-Entity
(	PUNCT	O	O
MB	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
potential	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
ICH	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
unclear	ADJ	O	O
if	ADP	O	O
they	PRON	O	O
are	VERB	O	O
a	DET	O	O
contraindication	NOUN	O	O
to	ADP	O	O
using	VERB	O	O
antithrombotic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O


METHODS	NOUN	O	O
:	PUNCT	O	O
Verapamil	PROPN	O	I-Entity
80	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
p.o	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
naphazoline	NOUN	O	I-Entity
and	CCONJ	O	O
xylometazoline	NOUN	O	I-Entity
on	ADP	O	O
analgesia	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
codeine	NOUN	O	I-Entity
,	PUNCT	O	O
fentanyl	NOUN	O	I-Entity
and	CCONJ	O	O
pentazocine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
cataleptic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
codine	NOUN	O	I-Entity
and	CCONJ	O	O
fentanyl	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
NA	PROPN	O	I-Entity
turnover	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
altered	VERB	O	O
by	ADP	O	O
analgesics	NOUN	O	O
except	ADP	O	O
for	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
(	PUNCT	O	O
0.2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
following	VERB	O	O
which	ADJ	O	O
the	DET	O	O
disappearance	NOUN	O	O
of	ADP	O	O
NA	PROPN	O	I-Entity
from	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
was	VERB	O	O
diminished	VERB	O	O
.	PUNCT	O	O

Modification	NOUN	O	O
by	ADP	O	O
propranolol	NOUN	O	I-Entity
of	ADP	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
induced	VERB	O	O
hypoglycaemia	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg	NUM	O	O
norethisterone	NOUN	O	I-Entity
daily	ADV	O	O
caused	VERB	O	O
reversion	NOUN	O	O
to	ADP	O	O
normal	ADJ	O	O
in	ADP	O	O
all	DET	O	O
57	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
cystic	NOUN	O	O
hyperplasia	NOUN	O	I-Entity
and	CCONJ	O	O
6	NUM	O	O
of	ADP	O	O
the	DET	O	O
8	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
atypical	ADJ	O	O
hyperplasia	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
125	NUM	O	O
infectious	ADJ	O	O
episodes	NOUN	O	O
in	ADP	O	O
116	NUM	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
receiving	VERB	O	O
myelosuppressive	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Growth	PROPN	O	B-Entity
retardation	NOUN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
significant	ADJ	O	O
in	ADP	O	O
both	DET	O	O
of	ADP	O	O
our	ADJ	O	O
series	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
propranolol	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
drug	NOUN	O	O
in	ADP	O	O
selected	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
idiopathic	ADJ	O	B-Entity
orthostatic	ADJ	O	I-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
encephalopathy	NOUN	O	I-Entity
was	VERB	O	O
probably	ADV	O	O
an	DET	O	O
idiosyncratic	ADJ	O	O
and	CCONJ	O	O
not	ADV	O	O
toxic	ADJ	O	O
or	CCONJ	O	O
allergic	ADJ	O	O
reaction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
exercise	NOUN	O	O
-	PUNCT	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
E-1	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
exercise	VERB	O	O
control	NOUN	O	O
(	PUNCT	O	O
EC	PROPN	O	O
)	PUNCT	O	O
groups	NOUN	O	O
exercised	VERB	O	O
daily	ADJ	O	O
for	ADP	O	O
thirty	NUM	O	O
days	NOUN	O	O
on	ADP	O	O
a	DET	O	O
treadmill	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
mph	NOUN	O	O
,	PUNCT	O	O
2%	NUM	O	O
grade	NOUN	O	O
while	ADP	O	O
animals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sedentary	ADJ	O	O
-	PUNCT	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
S	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
)	PUNCT	O	O
group	NOUN	O	O
remained	VERB	O	O
sedentary	ADJ	O	O
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
final	ADJ	O	O
exercise	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
S	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
and	CCONJ	O	O
E	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
animals	NOUN	O	O
received	VERB	O	O
a	DET	O	O
single	ADJ	O	O
subcutaneous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
excreted	VERB	O	O
acidic	ADJ	O	O
urine	NOUN	O	O
when	ADV	O	O
they	PRON	O	O
were	VERB	O	O
spared	VERB	O	O
from	ADP	O	O
renal	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
by	ADP	O	O
monosaccharides	NOUN	O	I-Entity
.	PUNCT	O	O

Paraplegia	PROPN	O	I-Entity
following	VERB	O	O
intrathecal	ADJ	O	O
methotrexate	NOUN	O	I-Entity
:	PUNCT	O	O
report	NOUN	O	O
of	ADP	O	O
a	DET	O	O
case	NOUN	O	O
and	CCONJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

desmethylimipramine	NOUN	O	I-Entity
(	PUNCT	O	O
0.3	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
propranolol	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

Fatty	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
tetracycline	ADV	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
intact	ADJ	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
rat	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
direct	ADJ	O	O
relationship	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
dose	NOUN	O	O
of	ADP	O	O
tetracycline	NOUN	O	I-Entity
and	CCONJ	O	O
hepatic	ADJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
.	PUNCT	O	O

Depressed	ADJ	O	O
hepatic	ADJ	O	O
secretion	NOUN	O	O
of	ADP	O	O
triglyceride	NOUN	O	I-Entity
accounted	VERB	O	O
only	ADV	O	O
for	ADP	O	O
30	NUM	O	O
to	PART	O	O
50%	NUM	O	O
of	ADP	O	O
accumulated	VERB	O	O
hepatic	ADJ	O	O
triglyceride	NOUN	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
additional	ADJ	O	O
mechanisms	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
the	DET	O	O
triglyceride	NOUN	O	I-Entity
-	PUNCT	O	O
rich	ADJ	O	O
fatty	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
tetracycline	ADV	O	I-Entity
.	PUNCT	O	O

Intracerebroventricular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
ethacrynic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
50%	NUM	O	O
convulsive	ADJ	O	I-Entity
dose	NOUN	O	O

-DOCSTART- (1361574)


-DOCSTART- (1449452)

For	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
sinus	ADJ	O	O
rhythm	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
the	DET	O	O
situation	NOUN	O	O
is	VERB	O	O
less	ADV	O	O
clear	ADJ	O	O
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
complication	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
rifampin	NOUN	O	I-Entity
.	PUNCT	O	O

Fluoxetine	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
gaining	VERB	O	O
increased	VERB	O	O
acceptance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
adolescent	ADJ	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
selective	ADJ	O	O
neuronal	ADJ	O	O
lesion	NOUN	O	O
of	ADP	O	O
rostral	ADJ	O	O
ventrolateral	ADJ	O	O
medulla	NOUN	O	O
on	ADP	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
neurogenic	ADJ	O	O
tone	NOUN	O	O
in	ADP	O	O
conscious	ADJ	O	O
,	PUNCT	O	O
unrestrained	ADJ	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Immunohistochemical	ADJ	O	O
staining	VERB	O	O
indicated	VERB	O	O
loss	NOUN	O	O
of	ADP	O	O
GFAP	PROPN	O	O
-	PUNCT	O	O
staining	VERB	O	O
already	ADV	O	O
at	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
oval	ADJ	O	O
focus	NOUN	O	O
situated	VERB	O	O
in	ADP	O	O
the	DET	O	O
center	NOUN	O	O
of	ADP	O	O
SNR	PROPN	O	O
while	ADP	O	O
sparing	VERB	O	O
medial	ADJ	O	O
and	CCONJ	O	O
lateral	ADJ	O	O
aspects	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
6	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
vasogenic	NOUN	O	B-Entity
edema	NOUN	O	I-Entity
covered	VERB	O	O
the	DET	O	O
lesioned	VERB	O	B-Entity
SNR	PROPN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
maximal	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
seen	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
polymer	NOUN	O	O
-	PUNCT	O	O
bound	VERB	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
that	DET	O	O
observed	VERB	O	O
in	ADP	O	O
those	DET	O	O
that	ADJ	O	O
received	VERB	O	O
free	ADJ	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
the	DET	O	O
unmodified	ADJ	O	O
parent	NOUN	O	O
HPMA	PROPN	O	I-Entity
copolymer	NOUN	O	O
and	CCONJ	O	O
free	ADJ	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
given	VERB	O	O
the	DET	O	O
HPMA	PROPN	O	I-Entity
copolymer	NOUN	O	O
conjugates	NOUN	O	O
containing	VERB	O	O
DOX	PROPN	O	I-Entity
exhibited	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	PROPN	O	O
response	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
-	PUNCT	O	O
course	NOUN	O	O
or	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
burning	NOUN	O	O
.	PUNCT	O	O

Serotonin	PROPN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
paranoia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
ventral	ADJ	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (1858969)

Severe	ADJ	O	O
polyneuropathy	NOUN	O	I-Entity
and	CCONJ	O	O
motor	NOUN	O	O
loss	NOUN	O	O
after	ADP	O	O
intrathecal	ADJ	O	O

Both	DET	O	O
cases	NOUN	O	O
developed	VERB	O	O
axonal	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
with	ADP	O	O
motor	NOUN	O	O
predominance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lower	ADJ	O	O
extremities	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
IT	NOUN	O	O
chemotherapy	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

When	ADV	O	O
circumflex	NOUN	O	O
artery	NOUN	O	O
blood	NOUN	O	O
flow	NOUN	O	O
was	VERB	O	O
maintained	VERB	O	O
constant	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
increases	NOUN	O	O
in	ADP	O	O
CxAD	PROPN	O	O
induced	VERB	O	O
by	ADP	O	O
cromakalim	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
pinacidil	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	X	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nitroglycerin	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
68	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
(	PUNCT	O	O
150	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
GABAergic	PROPN	O	O
and	CCONJ	O	O
dopaminergic	ADJ	O	O
systems	NOUN	O	O
by	ADP	O	O
measuring	VERB	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
GABA	PROPN	O	I-Entity
,	PUNCT	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
in	ADP	O	O
7	NUM	O	O
brain	NOUN	O	O
areas	NOUN	O	O
at	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

1.4	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
lindane	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
demonstrated	VERB	O	O
an	DET	O	O
ability	NOUN	O	O
to	PART	O	O
reduce	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
without	ADP	O	O
significantly	ADV	O	O
reducing	VERB	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
H	PROPN	O	I-Entity
concentration	NOUN	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
inspiratory	ADJ	O	O
gas	NOUN	O	O
was	VERB	O	O
0.7	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
operating	NOUN	O	O
conditions	NOUN	O	O
regarding	VERB	O	O
bleeding	VERB	O	I-Entity
were	VERB	O	O
estimated	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
manner	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
rose	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
from	ADP	O	O
the	DET	O	O
values	NOUN	O	O
before	ADP	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
returned	VERB	O	O
postoperatively	ADV	O	O
to	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
level	NOUN	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
except	ADP	O	O
the	DET	O	O
isoflurane	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O


have	VERB	O	O
equivalent	ADJ	O	O
anticonvulsant	ADJ	O	O
activity	NOUN	O	O
against	ADP	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
maximal	ADJ	O	O
electroshock	NOUN	O	O
(	PUNCT	O	O
MES	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
mice	NOUN	O	O
following	VERB	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
occurred	VERB	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
maximum	ADJ	O	O
phenytoin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (2818777)

Thus	ADV	O	O
,	PUNCT	O	O
"	PUNCT	O	O
stress	NOUN	O	O
"	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
adrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
230	NUM	O	O
pg	NOUN	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
6	NUM	O	O
h	PART	O	O
cause	VERB	O	O
a	DET	O	O
delayed	VERB	O	O
and	CCONJ	O	O
protracted	VERB	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3109094)

These	DET	O	O
changes	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
effectively	ADV	O	O
prevented	VERB	O	O
by	ADP	O	O
mesna	NOUN	O	I-Entity
.	PUNCT	O	O

Increase	VERB	O	O
in	ADP	O	O
intragastric	ADJ	O	O
pressure	NOUN	O	O
during	ADP	O	O
suxamethonium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
fasciculations	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
:	PUNCT	O	O
inhibition	NOUN	O	O
by	ADP	O	O
alfentanil	NOUN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
sodium	NOUN	O	B-Entity
salicylate	NOUN	O	I-Entity
,	PUNCT	O	O
ED50	PROPN	O	O
103	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
60	NUM	O	O
-	SYM	O	O
174	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
phenylbutazone	NOUN	O	I-Entity
,	PUNCT	O	O
59	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
-	SYM	O	O
70	NUM	O	O
)	PUNCT	O	O
converted	VERB	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
convulsant	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
200	NUM	O	O
mg	ADV	O	O
/	SYM	O	O
kg	X	O	O
,	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
convulsant	ADJ	O	O
one	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
applications	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
channel	NOUN	O	I-Entity
blockers	NOUN	O	I-Entity
parallel	VERB	O	O
their	ADJ	O	O
tissue	NOUN	O	O
selectivity	NOUN	O	O
.	PUNCT	O	O

Selectivity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
cerebrovascular	ADJ	O	O
bed	NOUN	O	O
makes	VERB	O	O
nimodipine	NOUN	O	I-Entity
potentially	ADV	O	O
useful	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
migraine	ADJ	O	B-Entity
headache	NOUN	O	I-Entity
,	PUNCT	O	O
dementia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

wt	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
PS	PROPN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
separated	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
2.5	NUM	O	O
mg/100	PROPN	O	O
g	NOUN	O	O
body	NOUN	O	O
wt	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
four	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
investigation	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
the	DET	O	O
neurotoxicity	NOUN	O	I-Entity
of	ADP	O	O
theophylline	NOUN	O	I-Entity
is	VERB	O	O
altered	VERB	O	O
in	ADP	O	O
advanced	ADJ	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

Cardiac	PROPN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
developed	VERB	O	O
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
colorectal	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
while	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
CDDP	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
5-fluorouracil	NUM	O	I-Entity
(	PUNCT	O	O
5-FU	NUM	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
determined	VERB	O	O
later	ADV	O	O
that	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
's	PART	O	O
tumor	NOUN	O	I-Entity
was	VERB	O	O
recurring	VERB	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
her	ADJ	O	O
hypertensive	ADJ	O	I-Entity
episode	NOUN	O	O
.	PUNCT	O	O

Cyclophosphamide	PROPN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
dosing	NOUN	O	O
as	ADP	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
these	DET	O	O
data	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
aminoglycoside	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
advanced	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
initial	ADJ	O	O
estimated	VERB	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
possibly	ADV	O	O
,	PUNCT	O	O
female	ADJ	O	O
gender	NOUN	O	O
all	DET	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


The	DET	O	O
results	NOUN	O	O
warrant	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
of	ADP	O	O
denopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
plasma	NOUN	O	O
lidocaine	NOUN	O	I-Entity
level	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
agents	NOUN	O	O
was	VERB	O	O
no	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
that	DET	O	O
in	ADP	O	O
patients	NOUN	O	O
not	ADV	O	O
on	ADP	O	O
beta	NOUN	O	O
blocking	VERB	O	O
agents	NOUN	O	O
.	PUNCT	O	O

Morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
newborn	ADJ	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
these	DET	O	O
neonates	NOUN	O	O
was	VERB	O	O
excessive	ADJ	O	O
(	PUNCT	O	O
60	NUM	O	O
and	CCONJ	O	O
90	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Toxic	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
flurazepam	NOUN	O	I-Entity
(	PUNCT	O	O
FZP	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
cats	NOUN	O	O
,	PUNCT	O	O
mice	NOUN	O	O
and	CCONJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Early	ADJ	O	O
infections	NOUN	O	I-Entity
in	ADP	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
on	ADP	O	O
cyclosporine	NOUN	O	I-Entity
.	PUNCT	O	O

Atrial	ADJ	O	B-Entity
thrombosis	NOUN	O	I-Entity
involving	VERB	O	O
the	DET	O	O
heart	NOUN	O	O
of	ADP	O	O
F-344	PROPN	O	O
rats	NOUN	O	O
ingesting	VERB	O	O
quinacrine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (6615679)

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
increased	VERB	O	O
rearings	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
stereotypies	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
blocked	VERB	O	O
by	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
DSP4	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6893265)

In	ADP	O	O
vivo	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
bepridil	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
(	PUNCT	O	O
i.v	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O


-DOCSTART- (7121659)

About	ADP	O	O
62%	NUM	O	O
of	ADP	O	O
the	DET	O	O
out	ADV	O	O
-	PUNCT	O	O
patients	NOUN	O	O
developed	VERB	O	O
scoline	ADJ	O	I-Entity
pain	NOUN	O	I-Entity
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
about	ADV	O	O
26%	NUM	O	O
among	ADP	O	O
the	DET	O	O
in	ADP	O	O
-	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Neither	CCONJ	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
induction	NOUN	O	O
agent	NOUN	O	O
(	PUNCT	O	O
Althesin	PROPN	O	I-Entity
or	CCONJ	O	O
Thiopentone	PROPN	O	I-Entity
)	PUNCT	O	O
nor	CCONJ	O	O
the	DET	O	O
salt	NOUN	O	O
preparation	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
used	VERB	O	O
(	PUNCT	O	O
chloride	NOUN	O	I-Entity
or	CCONJ	O	O
bromide	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
affected	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
scoline	NOUN	O	I-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (7369302)

Abnormalities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pupil	NOUN	O	O
and	CCONJ	O	O
visual	ADJ	O	O
-	PUNCT	O	O
evoked	VERB	O	O
potential	NOUN	O	O
in	ADP	O	O
quinine	NOUN	O	I-Entity
amblyopia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	B-Entity
disability	NOUN	O	I-Entity
and	CCONJ	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
seven	NUM	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
responsive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
after	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
challenge	NOUN	O	O
with	ADP	O	O
the	DET	O	O
mixed	VERB	O	O
dopamine	NOUN	O	I-Entity
agonist	NOUN	O	O
,	PUNCT	O	O
apomorphine	NOUN	O	I-Entity
,	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
fluoxetine	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
twice	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
11	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

A	DET	O	O
large	ADJ	O	O
population	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
study	NOUN	O	O
of	ADP	O	O
trimethoprim	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
sulfamethoxazole	NOUN	O	I-Entity
,	PUNCT	O	O
trimethoprim	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cephalexin	NOUN	O	I-Entity
for	ADP	O	O
uncommon	ADJ	O	O
serious	ADJ	O	O
drug	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (7492040)

-DOCSTART- (7671401)

Three	NUM	O	O
young	ADJ	O	O
infants	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
of	ADP	O	O
birth	NOUN	O	O
weight	NOUN	O	O
<	SYM	O	O
1,500	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
experienced	VERB	O	O
myoclonus	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
lorazepam	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
second	ADJ	O	O
event	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
death	NOUN	O	O
,	PUNCT	O	O
within	ADP	O	O
10	NUM	O	O
to	PART	O	O
60	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O


Group	PROPN	O	O
5	NUM	O	O
received	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
combination	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
followed	VERB	O	O
later	ADV	O	O
by	ADV	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
flumazenil	NOUN	O	I-Entity
.	PUNCT	O	O

Neither	CCONJ	O	O
SOD	PROPN	O	O
nor	CCONJ	O	O
DMTU	PROPN	O	I-Entity
affected	VERB	O	O
the	DET	O	O
renal	ADJ	O	O
cortical	ADJ	O	O
GM	PROPN	O	I-Entity
content	NOUN	O	O
in	ADP	O	O
GM	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
cardiomyocytes	NOUN	O	O
to	PART	O	O
synthesize	VERB	O	O
DNA	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	PART	O	O
experimentally	ADV	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
adult	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (8312343)

Only	ADV	O	O
a	DET	O	O
few	ADJ	O	O
reports	NOUN	O	O
exist	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
SSRIs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	O
atrial	NOUN	O	O
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
papillary	ADJ	O	O
muscle	NOUN	O	O
contractile	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
isoproterenol	NOUN	O	I-Entity
were	VERB	O	O
reduced	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
responses	NOUN	O	O
to	ADP	O	O
calcium	NOUN	O	I-Entity
were	VERB	O	O
normal	ADJ	O	O
or	CCONJ	O	O
enhanced	ADJ	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
this	DET	O	O
schedule	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
animals	NOUN	O	O
'	PART	O	O
hearts	NOUN	O	O
appeared	VERB	O	O
normal	ADJ	O	O
after	ADP	O	O
sacrifice	NOUN	O	O
and	CCONJ	O	O
ICRF-187	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
given	VERB	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

Surprisingly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
F1	PROPN	O	O
hybrid	NOUN	O	O
tumors	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
hemorrhagic	ADJ	O	I-Entity
and	CCONJ	O	O
had	VERB	O	O
hemoglobin	NOUN	O	O
content	NOUN	O	O
and	CCONJ	O	O
outward	ADJ	O	O
appearance	NOUN	O	O
identical	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
BN	PROPN	O	O
.	PUNCT	O	O


Diltiazem	PROPN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
also	ADV	O	O
prevented	VERB	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
percentage	NOUN	O	O
segmental	NOUN	O	O
shortening	VERB	O	O
from	ADP	O	O
34	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
CD-832	PROPN	O	I-Entity
improves	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
during	ADP	O	O
ISO	PROPN	O	I-Entity
infusion	NOUN	O	O
with	ADP	O	O
stenosis	NOUN	O	I-Entity
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
negative	ADJ	O	O
chronotropic	ADJ	O	O
property	NOUN	O	O
of	ADP	O	O
CD-832	PROPN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
major	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
CD-832	PROPN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Four	NUM	O	O
studies	NOUN	O	O
published	VERB	O	O
since	ADP	O	O
December	PROPN	O	O
,	PUNCT	O	O
1995	NUM	O	O
,	PUNCT	O	O
reported	VERB	O	O
that	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
(	PUNCT	O	O
VTE	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
(	PUNCT	O	O
OCs	PROPN	O	I-Entity
)	PUNCT	O	O
containing	VERB	O	O
the	DET	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
progestagens	NOUN	O	I-Entity
gestodene	NOUN	O	I-Entity
or	CCONJ	O	O
desogestrel	NOUN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
OCs	PROPN	O	I-Entity
containing	VERB	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
progestagens	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
torsades	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
presumable	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
d	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sotalol	NOUN	O	I-Entity
for	ADP	O	O
sustained	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

Neither	DET	O	O
ECG	PROPN	O	O
[	PUNCT	O	O
sinus	ADJ	O	O
-	PUNCT	O	O
cycle	NOUN	O	O
length	NOUN	O	O
(	PUNCT	O	O
SCL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
QT	PROPN	O	O
or	CCONJ	O	O
QTc	PROPN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
U	PROPN	O	O
wave	NOUN	O	O
]	PUNCT	O	O
nor	CCONJ	O	O
clinical	ADJ	O	O
parameters	NOUN	O	O
identified	VERB	O	O
patients	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
ATRA	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
valid	ADJ	O	O
therapeutic	ADJ	O	O
choice	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
APL	PROPN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
procoagulant	NOUN	O	O
tendency	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
completely	ADV	O	O
corrected	VERB	O	O
.	PUNCT	O	O

About	ADV	O	O
2/3	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
both	DET	O	O
Gamma	PROPN	O	O
Knife	PROPN	O	O
and	CCONJ	O	O
radiofrequency	NOUN	O	O
groups	NOUN	O	O
showed	VERB	O	O
improvements	NOUN	O	O
in	ADP	O	O
bradykinesia	NOUN	O	I-Entity
and	CCONJ	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
when	ADV	O	O
considered	VERB	O	O
as	ADP	O	O
a	DET	O	O
group	NOUN	O	O
neither	CCONJ	O	O
the	DET	O	O
Gamma	PROPN	O	O
Knife	PROPN	O	O
nor	CCONJ	O	O
the	DET	O	O
radiofrequency	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
UPDRS	PROPN	O	O
scores	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
only	ADJ	O	O
practical	ADJ	O	O
technique	NOUN	O	O
available	ADJ	O	O
in	ADP	O	O
certain	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
those	DET	O	O
who	NOUN	O	O
take	VERB	O	O
anticoagulants	NOUN	O	O
,	PUNCT	O	O
have	VERB	O	O
bleeding	NOUN	O	I-Entity
diatheses	NOUN	O	O
or	CCONJ	O	O
serious	ADJ	O	O
systemic	ADJ	O	O
medical	ADJ	O	O
illnesses	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
relative	ADJ	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
ergic	ADJ	O	O
deficiency	NOUN	O	O
might	VERB	O	O
occur	VERB	O	O
because	ADP	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
mimetic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
strikingly	ADV	O	O
effective	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
female	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	O
cytolytic	ADJ	O	O
hepatitis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
meloxicam	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
subchronic	ADJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NOARG	PROPN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
NOS	PROPN	O	O
neurons	NOUN	O	O
in	ADP	O	O
areas	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
motor	NOUN	O	O
control	NOUN	O	O
.	PUNCT	O	O

Catalepsy	PROPN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
at	ADP	O	O
the	DET	O	O
beginning	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (10713017)

:	PUNCT	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
surveillance	NOUN	O	O
study	NOUN	O	O
on	ADP	O	O
patients	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
at	ADP	O	O
12	NUM	O	O
large	ADJ	O	O
referral	ADJ	O	O
centers	NOUN	O	O
in	ADP	O	O
North	PROPN	O	O
America	PROPN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
identifiable	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
were	VERB	O	O
classed	VERB	O	O
as	ADP	O	O
PPH	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
are	VERB	O	O
meritorious	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
do	VERB	O	O
exist	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
are	VERB	O	O
relatively	ADV	O	O
rare	ADJ	O	O
in	ADP	O	O
a	DET	O	O
given	VERB	O	O
individual	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
given	VERB	O	O
the	DET	O	O
extremely	ADV	O	O
widespread	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
some	DET	O	O
are	VERB	O	O
quite	ADV	O	O
common	ADJ	O	O
,	PUNCT	O	O
particularly	ADV	O	O
HITT	PROPN	O	I-Entity
and	CCONJ	O	O
osteoporosis	NOUN	O	I-Entity
.	PUNCT	O	O

Patterns	NOUN	O	O
of	ADP	O	O
sulfadiazine	NOUN	O	I-Entity
acute	ADJ	O	B-Entity
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Sulfadiazine	PROPN	O	I-Entity
acute	ADJ	O	B-Entity
nephrotoxicity	NOUN	O	I-Entity
is	VERB	O	O
reviving	VERB	O	O
specially	ADV	O	O
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
toxoplasmosis	NOUN	O	I-Entity
in	ADP	O	O
HIV	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
courses	NOUN	O	O
of	ADP	O	O
liposomal	NOUN	O	O
doxorubicin	NOUN	O	I-Entity
administered	VERB	O	O
on	ADP	O	O
this	DET	O	O
protocol	NOUN	O	O
was	VERB	O	O
2	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
:	PUNCT	O	O
1	NUM	O	O
-	PUNCT	O	O
12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
olanzapine	NOUN	O	I-Entity
vs	ADP	O	O
placebo	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
EPSs	NOUN	O	I-Entity
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
series	NOUN	O	O
of	ADP	O	O
tests	NOUN	O	O
on	ADP	O	O
various	ADJ	O	O
parameters	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
driving	VERB	O	O
simulator	NOUN	O	O
performance	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
12	NUM	O	O
healthy	ADJ	O	O
drivers	NOUN	O	O
,	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
pupil	NOUN	O	B-Entity
dilation	NOUN	O	I-Entity
using	VERB	O	O
guttae	NOUN	O	O
tropicamide	ADV	O	I-Entity
1%	NUM	O	O
.	PUNCT	O	O

Toleration	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
converting	VERB	O	I-Entity
enzyme	NOUN	O	I-Entity
inhibitors	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
:	PUNCT	O	O
results	NOUN	O	O
from	ADP	O	O
the	DET	O	O
ATLAS	PROPN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Their	ADJ	O	O
combined	ADJ	O	O
cardiac	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
independent	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
each	DET	O	O
drug	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
they	PRON	O	O
may	VERB	O	O
also	ADV	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
cocaethylene	NOUN	O	I-Entity
(	PUNCT	O	O
CE	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
cocaine	NOUN	O	I-Entity
metabolite	NOUN	O	O
formed	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
ethanol	NOUN	O	I-Entity
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
resting	VERB	O	O
and	CCONJ	O	O
peak	ADJ	O	O
exercise	NOUN	O	O
abnormal	ADJ	O	B-Entity
left	VERB	O	I-Entity
ventricular	NOUN	O	I-Entity
filling	NOUN	O	I-Entity
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
38	NUM	O	O
and	CCONJ	O	O
35%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
19	NUM	O	O
and	CCONJ	O	O
9%	NUM	O	O
of	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.11	NUM	O	O
and	CCONJ	O	O
0.02	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (11395263)

Although	ADP	O	O
both	DET	O	O
dl	NOUN	O	O
-	PUNCT	O	O
sotalol	NOUN	O	I-Entity
and	CCONJ	O	O
azimilide	NOUN	O	I-Entity
rarely	ADV	O	O
induced	VERB	O	O
EADs	NOUN	O	O
in	ADP	O	O
canine	NOUN	O	O
left	VERB	O	O
ventricles	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
produced	VERB	O	O
frequent	ADJ	O	O
EADs	NOUN	O	O
in	ADP	O	O
rabbits	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADJ	O	O
more	ADV	O	O
pronounced	ADJ	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
.	PUNCT	O	O

An	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
TDR	PROPN	O	O
by	ADP	O	O
dl	NOUN	O	O
-	PUNCT	O	O
sotalol	NOUN	O	I-Entity
facilitated	VERB	O	O
transmural	ADJ	O	O
propagation	NOUN	O	O
of	ADP	O	O
EADs	NOUN	O	O
that	ADJ	O	O
initiated	VERB	O	O
multiple	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
TdP	PROPN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
of	ADP	O	O
6	NUM	O	O
rabbit	NOUN	O	O
left	VERB	O	O
ventricles	NOUN	O	O
.	PUNCT	O	O


In	ADP	O	O
the	DET	O	O
transgenic	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
kanamycin	VERB	O	I-Entity
increased	VERB	O	O
the	DET	O	O
threshold	NOUN	O	O
by	ADP	O	O
only	ADV	O	O
15	NUM	O	O
dB	NOUN	O	O
over	ADP	O	O
the	DET	O	O
respective	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (11708428)

Grade	PROPN	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
nonhematologic	ADJ	O	O
toxicity	NOUN	O	I-Entity
included	VERB	O	O
nausea	NOUN	O	I-Entity
in	ADP	O	O
17	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
emesis	NOUN	O	I-Entity
in	ADP	O	O
14	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
fatigue	NOUN	O	I-Entity
in	ADP	O	O
9	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
mucositis	NOUN	O	I-Entity
and/or	CCONJ	O	O
stomatitis	NOUN	O	I-Entity
in	ADP	O	O
8	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
constipation	NOUN	O	I-Entity
in	ADP	O	O
6	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
5	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
hand	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
foot	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
skin	NOUN	O	B-Entity
reactions	NOUN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
with	ADP	O	O
diclofenac	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
dysmenorrhea	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
open	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
cross	VERB	O	O
-	PUNCT	O	O
over	ADP	O	O
trial	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
GTN	PROPN	O	I-Entity
has	VERB	O	O
a	DET	O	O
reduced	VERB	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
by	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
DCF	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
dysmenorrhea	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
glomerulosclerosis	NOUN	O	I-Entity
index	NOUN	O	O
(	PUNCT	O	O
GSI	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
6.21	NUM	O	O
%	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
respectively	ADV	O	O
25.35	NUM	O	O
%	NOUN	O	O
and	CCONJ	O	O
30.49	NUM	O	O
%	NOUN	O	O
at	ADP	O	O
14	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PAN	PROPN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Persistent	ADJ	O	O
sterile	ADJ	O	O
leukocyturia	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
impaired	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
in	ADP	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
type	NOUN	O	I-Entity
1-infected	VERB	O	I-Entity
children	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
indinavir	NOUN	O	I-Entity
.	PUNCT	O	O

Outcomes	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
admitted	VERB	O	O
for	ADP	O	O
possible	ADJ	O	O
MI	PROPN	O	I-Entity
after	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
both	DET	O	O
adenosine	NOUN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
although	ADP	O	O
agonists	NOUN	O	O
of	ADP	O	O
A1	NOUN	O	O
receptors	NOUN	O	O
seem	VERB	O	O
to	PART	O	O
have	VERB	O	O
stronger	ADJ	O	O
influence	NOUN	O	O
on	ADP	O	O
it	PRON	O	O
.	PUNCT	O	O


Central	ADJ	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
for	ADP	O	O
lumbar	NOUN	O	O
plexus	NOUN	O	O
block	NOUN	O	O
:	PUNCT	O	O

Myotonia	PROPN	O	B-Entity
congenita	NOUN	O	I-Entity
(	PUNCT	O	O
MC	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
a	DET	O	O
defect	NOUN	O	O
in	ADP	O	O
the	DET	O	O
skeletal	ADJ	O	O
muscle	NOUN	O	O
chloride	NOUN	O	I-Entity
channel	NOUN	O	O
function	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
cause	VERB	O	O
sustained	ADJ	O	B-Entity
membrane	NOUN	O	I-Entity
depolarisation	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
sought	VERB	O	O
to	PART	O	O
generate	VERB	O	O
information	NOUN	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
the	DET	O	O
interictal	ADJ	O	O
period	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
with	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
serum	NOUN	O	O
sFas	PROPN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
aspartate	ADJ	O	I-Entity
aminotransferase	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.613	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (14616590)

In	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
cross	NOUN	O	O
-	PUNCT	O	O
over	PART	O	O
study	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
received	VERB	O	O
a	DET	O	O
single	ADJ	O	O
intravenous	ADJ	O	O
bolus	NOUN	O	O
injection	NOUN	O	O
of	ADP	O	O
2.5	NUM	O	O
mg.kg-1	NOUN	O	O
propofol	NOUN	O	I-Entity
.	PUNCT	O	O

Randomized	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
comparing	VERB	O	O
VNR	PROPN	O	I-Entity
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	I-Entity
were	VERB	O	O
searched	VERB	O	O
in	ADP	O	O
Medline	PROPN	O	O
,	PUNCT	O	O
Embase	PROPN	O	O
,	PUNCT	O	O
Evidence	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
Medicine	PROPN	O	O
Reviews	PROPN	O	O
databases	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
Cochrane	PROPN	O	O
library	NOUN	O	O
from	ADP	O	O
1987	NUM	O	O
to	ADP	O	O
2002	NUM	O	O
.	PUNCT	O	O

Histopathological	ADJ	O	O
examination	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
to	PART	O	O
confirm	VERB	O	O
the	DET	O	O
myocardial	ADJ	O	O
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
discussed	VERB	O	O
herein	ADV	O	O
initially	ADV	O	O
appeared	VERB	O	O
to	PART	O	O
be	VERB	O	O
neurogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	VERB	O	I-Entity
(	PUNCT	O	O
DI	PROPN	O	I-Entity
)	PUNCT	O	O
secondary	ADJ	O	O
to	ADP	O	O
a	DET	O	O
traumatic	ADJ	O	B-Entity
brain	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
document	NOUN	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
that	ADP	O	O
mitochondrial	ADJ	O	B-Entity
oxidative	ADJ	O	I-Entity
damage	NOUN	O	I-Entity
precedes	VERB	O	O
nitrative	ADJ	O	O
damage	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
one	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
switching	VERB	O	O
over	ADP	O	O
nifekalant	NOUN	O	I-Entity
to	ADP	O	O
sotalol	VERB	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
short	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
ST	PROPN	O	O
elevation	NOUN	O	O
was	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
ECG	PROPN	O	O
monitoring	NOUN	O	O
at	ADP	O	O
almost	ADV	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
for	ADP	O	O
three	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

17.5	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
olanzapine	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
40.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

olanzapine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
groups	NOUN	O	O
displayed	VERB	O	O
significant	ADJ	O	O
insulin	NOUN	O	B-Entity
resistance	NOUN	O	I-Entity
and	CCONJ	O	O
impairment	NOUN	O	O
of	ADP	O	O
glucose	NOUN	O	I-Entity
effectiveness	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
53	NUM	O	O
major	ADJ	O	O
hemorrhages	NOUN	O	I-Entity
,	PUNCT	O	O
for	ADP	O	O
an	DET	O	O
annual	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
10.0%	NUM	O	O
,	PUNCT	O	O
including	VERB	O	O
24	NUM	O	O
(	PUNCT	O	O
45.3%	NUM	O	O
)	PUNCT	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
and	CCONJ	O	O
five	NUM	O	O
(	PUNCT	O	O
9.4%	NUM	O	O
)	PUNCT	O	O
fatal	ADJ	O	O
bleeds	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
hemorrhage	NOUN	O	I-Entity
was	VERB	O	O
high	ADJ	O	O
in	ADP	O	O
this	DET	O	O
old	ADJ	O	O
,	PUNCT	O	O
frail	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
excluding	VERB	O	O
fatalities	NOUN	O	O
,	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
no	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
sequelae	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
stroke	NOUN	O	I-Entity
rate	NOUN	O	O
on	ADP	O	O
warfarin	NOUN	O	I-Entity
was	VERB	O	O
low	ADJ	O	O
,	PUNCT	O	O
demonstrating	VERB	O	O
how	ADV	O	O
effective	ADJ	O	O
warfarin	ADJ	O	I-Entity
treatment	NOUN	O	O
is	VERB	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
antagonizes	VERB	O	O

Adult	NOUN	O	O
male	NOUN	O	O
Swiss	PROPN	O	O
Webster	PROPN	O	O
mice	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
-	SYM	O	O
32	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
-	SYM	O	O
0.25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
saline	NOUN	O	O
10	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
70	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
pentylenetetrazole	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
HT	PROPN	O	O
on	ADP	O	O
mortality	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
,	PUNCT	O	O
transient	ADJ	O	B-Entity
ischaemic	NOUN	O	I-Entity
attacks	NOUN	O	I-Entity
,	PUNCT	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
colorectal	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
ovarian	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
dementia	NOUN	O	I-Entity
,	PUNCT	O	O
fractures	NOUN	O	I-Entity
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

HT	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
indicated	VERB	O	O
for	ADP	O	O
the	DET	O	O
routine	ADJ	O	O
management	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


The	DET	O	O
major	ADJ	O	O
triggering	NOUN	O	O
factors	NOUN	O	O
of	ADP	O	O
Tdp	PROPN	O	I-Entity
were	VERB	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
sudden	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

1.5%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
parasympathetic	ADJ	O	O
blockade	NOUN	O	O
by	ADP	O	O
atropine	NOUN	O	I-Entity
on	ADP	O	O
HR	PROPN	O	O
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	DET	O	O
strains	NOUN	O	O
.	PUNCT	O	O

-DOCSTART- (16867246)

Physical	ADJ	O	O
training	NOUN	O	O
decreases	VERB	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
subsequent	ADJ	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dopamine	NOUN	O	I-Entity
precursor	NOUN	O	O
levodopa	NOUN	O	I-Entity
enhances	VERB	O	O
learning	VERB	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
second	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
minocycline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vasculitis	NOUN	O	I-Entity
satisfying	VERB	O	O
the	DET	O	O
criteria	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
retrospective	ADJ	O	O
chart	NOUN	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
organ	ADJ	O	O
transplant	NOUN	O	O
database	NOUN	O	O
identified	VERB	O	O
51	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
43	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
8	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
transplanted	VERB	O	O
for	ADP	O	O
benign	ADJ	O	O
HBV	PROPN	O	O
-	PUNCT	O	O
related	VERB	O	O
cirrhotic	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
between	ADP	O	O
June	PROPN	O	O
2002	NUM	O	O
and	CCONJ	O	O
December	PROPN	O	O
2004	NUM	O	O
who	NOUN	O	O
had	VERB	O	O
survived	VERB	O	O
more	ADJ	O	O
than	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Eslicarbazepine	PROPN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
BIA	PROPN	O	B-Entity
2	NUM	O	I-Entity
-	SYM	O	I-Entity
093	NUM	O	I-Entity
,	PUNCT	O	O
S-(-)-10-acetoxy-10,11-dihydro-5H	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dibenzo	PROPN	O	I-Entity
/	PUNCT	O	I-Entity
b	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
f	PROPN	O	I-Entity
/	SYM	O	I-Entity
azepine-5-carboxamide	ADV	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
novel	ADJ	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
now	ADV	O	O
in	ADP	O	O
Phase	PROPN	O	O
III	NUM	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
,	PUNCT	O	O
designed	VERB	O	O
with	ADP	O	O
the	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
improving	VERB	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
structurally	ADV	O	O
related	VERB	O	O
drugs	NOUN	O	O
carbamazepine	NOUN	O	I-Entity
(	PUNCT	O	O
CBZ	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
oxcarbazepine	NOUN	O	I-Entity
(	PUNCT	O	O
OXC	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
steroidal	ADJ	O	I-Entity
anti	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
inflammatory	ADJ	O	I-Entity
drugs	NOUN	O	I-Entity
(	PUNCT	O	O
NSAIDs	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
autosomal	ADJ	O	O
recessive	ADJ	O	O
disorder	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	O
copper	NOUN	O	I-Entity
metabolism	NOUN	O	O
with	ADP	O	O
consequent	ADJ	O	O
copper	NOUN	O	I-Entity
accumulation	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
many	ADJ	O	O
tissues	NOUN	O	O
and	CCONJ	O	O
consequent	ADJ	O	O
hepatic	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
neurologic	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
psychiatric	ADJ	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (17379047)

Comparison	NOUN	O	O
of	ADP	O	O
valsartan	NOUN	O	I-Entity
/	SYM	O	O
hydrochlorothiazide	NOUN	O	I-Entity
combination	NOUN	O	O
therapy	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
up	ADP	O	O
to	ADP	O	O
320/25	NUM	O	O
mg	NUM	O	O
versus	ADP	O	O
monotherapy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
study	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
hypertensive	ADJ	O	I-Entity
adults	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
population	NOUN	O	O
,	PUNCT	O	O
combination	NOUN	O	O
therapies	NOUN	O	O
with	ADP	O	O
VAL	PROPN	O	I-Entity
/	SYM	O	O
HCTZ	PROPN	O	I-Entity
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significantly	ADV	O	O
greater	ADJ	O	O
BP	PROPN	O	O
reductions	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
either	DET	O	O
monotherapy	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
less	ADJ	O	O
hypokalemia	NOUN	O	I-Entity
than	ADP	O	O
HCTZ	PROPN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

-DOCSTART- (17384765)

(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
MD	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
7.1%	NUM	O	O
(	PUNCT	O	O
n=	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
had	VERB	O	O
a	DET	O	O
panic	NOUN	O	B-Entity
attack	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
480-mg	NUM	O	O
caffeine	NOUN	O	I-Entity
challenge	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
chi(2)(3	PROPN	O	O
)	PUNCT	O	O
=	SYM	O	O
16.22	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
MD	PROPN	O	I-Entity
had	VERB	O	O
a	DET	O	O
lower	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
test	NOUN	O	O
than	ADP	O	O
all	ADJ	O	O
the	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
(	PUNCT	O	O
2-way	NUM	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
,	PUNCT	O	O
group	NOUN	O	O
by	ADP	O	O
time	NOUN	O	O
interaction	NOUN	O	O
with	ADP	O	O
Greenhouse	PROPN	O	O
-	PUNCT	O	O
Geisser	PROPN	O	O
correction	NOUN	O	O
:	PUNCT	O	O
F(3,762	PUNCT	O	O
)	PUNCT	O	O
=	SYM	O	O
2.85	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.026	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (17496739)

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Local	ADJ	O	O
anesthesia	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
temporary	ADJ	O	O
ipsilateral	ADJ	O	O
vocal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
paralysis	NOUN	O	I-Entity
in	ADP	O	O
almost	ADV	O	O
half	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
put	VERB	O	O
on	ADP	O	O
aspirin	NOUN	O	I-Entity
following	VERB	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
took	VERB	O	O
ibuprofen	NOUN	O	I-Entity
for	ADP	O	O
fever	NOUN	O	I-Entity
for	ADP	O	O
nearly	ADV	O	O
a	DET	O	O
week	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
presentation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
blocking	VERB	O	O
nociceptive	ADJ	O	O
input	NOUN	O	O
from	ADP	O	O
surgical	ADJ	O	O
sites	NOUN	O	O
,	PUNCT	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
might	VERB	O	O
directly	ADV	O	O
modulate	VERB	O	O
inflammation	NOUN	O	I-Entity
.	PUNCT	O	O

Quantitative	PROPN	O	O
,	PUNCT	O	O
real	ADJ	O	O
-	PUNCT	O	O
time	NOUN	O	O
polymerase	NOUN	O	O
chain	NOUN	O	O
reaction	NOUN	O	O
also	ADV	O	O
demonstrated	VERB	O	O
significant	ADJ	O	O
increases	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
p75(NTR	NOUN	O	O
)	PUNCT	O	O
mRNA	NOUN	O	O
in	ADP	O	O
DRG	PROPN	O	O
with	ADP	O	O
intermediate	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
CYP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
lateral	ADJ	O	O
position	NOUN	O	O
with	ADP	O	O
operative	ADJ	O	O
side	NOUN	O	O
down	PART	O	O
,	PUNCT	O	O
patients	NOUN	O	O
recived	VERB	O	O
10	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
2mls	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
0.5%	NUM	O	O
hyperbaric	NOUN	O	O
bupivacaine	NOUN	O	I-Entity
through	ADP	O	O
a	DET	O	O
25-gauge	NUM	O	O
spinal	ADJ	O	O
needle	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
(	PUNCT	O	O
10.8%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
(	PUNCT	O	O
2.7%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
unilateral	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
P=	PROPN	O	O
0.17	NUM	O	O
required	VERB	O	O
epinephrine	NOUN	O	I-Entity
infusion	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Frequent	NOUN	O	O
and	CCONJ	O	O
early	ADJ	O	O
monitoring	NOUN	O	O
for	ADP	O	O
these	DET	O	O
toxicities	NOUN	O	I-Entity
is	VERB	O	O
warranted	VERB	O	O
in	ADP	O	O
developing	VERB	O	O
countries	NOUN	O	O
where	ADV	O	O
generic	ADJ	O	O
HAART	PROPN	O	O
is	VERB	O	O
increasingly	ADV	O	O
available	ADJ	O	O
.	PUNCT	O	O

Autoimmune	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
,	PUNCT	O	O
viral	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
malignant	ADJ	O	O
neoplasms	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
diseases	NOUN	O	O
with	ADP	O	O
a	DET	O	O
known	VERB	O	O
relationship	NOUN	O	O
to	ADP	O	O
membranous	ADJ	O	B-Entity
glomerulonephritis	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
found	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
In	ADP	O	O
type	NOUN	O	B-Entity
2	NUM	O	I-Entity
diabetic	ADJ	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
cases	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
CAD	PROPN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
retrospectively	ADV	O	O
with	ADP	O	O
controls	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
postoperative	ADJ	O	O
complications	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
aprotinin	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
unselected	ADJ	O	O
,	PUNCT	O	O
consecutive	ADJ	O	O
cohort	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
metabolic	NOUN	O	O
responses	VERB	O	O
to	ADP	O	O
isoprenaline	VERB	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
(	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
circulating	VERB	O	O
glucose	NOUN	O	I-Entity
,	PUNCT	O	O
lactate	NOUN	O	I-Entity
and	CCONJ	O	O
free	ADJ	O	O
fatty	ADJ	O	B-Entity
acids	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
all	DET	O	O
blocked	VERB	O	O
by	ADP	O	O
(	PUNCT	O	O
-)-propranolol	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
isomers	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
exhibited	VERB	O	O
similar	ADJ	O	O
local	ADJ	O	O
anaesthetic	ADJ	O	O
potencies	NOUN	O	O
on	ADP	O	O
an	DET	O	O
isolated	ADJ	O	O
frog	NOUN	O	O
nerve	NOUN	O	O
preparation	NOUN	O	O
at	ADP	O	O
a	DET	O	O
level	NOUN	O	O
approximately	ADV	O	O
three	NUM	O	O
times	NOUN	O	O
that	DET	O	O
of	ADP	O	O
procaine	NOUN	O	I-Entity
.	PUNCT	O	O

Topotecan	PROPN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
radiotherapy	ADJ	O	O
in	ADP	O	O
unresectable	ADJ	O	O
glioblastoma	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
phase	NOUN	O	O
2	NUM	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
hematological	ADJ	O	O
toxicities	NOUN	O	I-Entity
was	VERB	O	O
low	ADJ	O	O
and	CCONJ	O	O
grade	NOUN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
hematological	ADJ	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
20	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mainly	ADV	O	O
lymphopenia	NOUN	O	I-Entity
and	CCONJ	O	O
neutropenia	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

-DOCSTART- (19263707)

Anti	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
thyroid	ADJ	O	I-Entity
drugs	NOUN	O	I-Entity
,	PUNCT	O	O
like	ADP	O	O
carbimazole	NOUN	O	I-Entity
and	CCONJ	O	O
propylthiouracil	NOUN	O	I-Entity
(	PUNCT	O	O
PTU	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
commonly	ADV	O	O
prescribed	VERB	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
.	PUNCT	O	O

Men	NOUN	O	O
in	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
experienced	VERB	O	O
fewer	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarctions	NOUN	O	I-Entity
and	CCONJ	O	O
women	NOUN	O	O
experienced	VERB	O	O
fewer	ADJ	O	O
ischemic	ADJ	O	O
strokes	NOUN	O	I-Entity
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
thiobarbituric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
reactive	ADJ	O	O
substances	NOUN	O	O
(	PUNCT	O	O
TBARSs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O


NSCLC	PROPN	O	I-Entity
continues	VERB	O	O
.	PUNCT	O	O

-DOCSTART- (19841052)

Of	ADP	O	O
these	DET	O	O
,	PUNCT	O	O
137	NUM	O	O
acquired	VERB	O	O
HIV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
during	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
:	PUNCT	O	O
Smoking	NOUN	O	O
of	ADP	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
independent	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
HIV	PROPN	O	B-Entity
seroconversion	NOUN	O	I-Entity
among	ADP	O	O
people	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
injection	NOUN	O	O
drug	NOUN	O	O
users	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
widely	ADV	O	O
used	VERB	O	O
chemotherapeutic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
5-fluorouracil	PROPN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
readily	ADV	O	O
crosses	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
and	CCONJ	O	O
so	ADV	O	O
could	VERB	O	O
have	VERB	O	O
a	DET	O	O
direct	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
brain	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Liver	ADV	O	O
-	PUNCT	O	O
specific	ADJ	O	O
ablation	NOUN	O	O
of	ADP	O	O
integrin	NOUN	O	O
-	PUNCT	O	O
linked	VERB	O	O
kinase	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
enhanced	VERB	O	O
and	CCONJ	O	O
prolonged	VERB	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
and	CCONJ	O	O
hepatomegaly	NOUN	O	I-Entity
after	ADP	O	O
phenobarbital	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Livers	NOUN	O	O
were	VERB	O	O
harvested	VERB	O	O
on	ADP	O	O
2	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
days	NOUN	O	O
during	ADP	O	O
PB	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Decreased	VERB	O	O
Expression	NOUN	O	O
of	ADP	O	O
Na	PROPN	O	I-Entity
/	SYM	O	O
K	PROPN	O	I-Entity
-	PUNCT	O	O
ATPase	PROPN	O	O
,	PUNCT	O	O
NHE3	PROPN	O	O
,	PUNCT	O	O
NBC1	PROPN	O	O
,	PUNCT	O	O
AQP1	PROPN	O	O
and	CCONJ	O	O
OAT	PROPN	O	O
in	ADP	O	O
Gentamicin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
Nephropathy	PROPN	O	I-Entity
.	PUNCT	O	O

Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
male	NOUN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
200~250	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
subcutaneously	ADV	O	O
injected	VERB	O	O
with	ADP	O	O
gentamicin	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
tubular	ADJ	O	O
transporters	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
immunoblotting	VERB	O	O
and	CCONJ	O	O
immunohistochemistry	NOUN	O	O
.	PUNCT	O	O

Longitudinal	ADJ	O	O
association	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
progression	NOUN	O	O
and	CCONJ	O	O
psychological	ADJ	O	O
health	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	O
.	PUNCT	O	O

Five	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
SE	PROPN	O	I-Entity
,	PUNCT	O	O
CCR2	PROPN	O	O
staining	VERB	O	O
in	ADP	O	O
neurons	NOUN	O	O
and	CCONJ	O	O
glial	ADJ	O	O
cells	NOUN	O	O
was	VERB	O	O
examined	VERB	O	O
using	VERB	O	O
imunohistochemical	ADJ	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

Increased	VERB	O	O
numbers	NOUN	O	O
of	ADP	O	O
neurons	NOUN	O	O
that	ADJ	O	O
expressed	VERB	O	O
CCR2	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
following	VERB	O	O
SE	PROPN	O	I-Entity
.	PUNCT	O	O

-DOCSTART- (20046642)

To	PART	O	O
best	ADJ	O	O
of	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
second	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
carbamazepine	NOUN	O	I-Entity
induced	VERB	O	O
myocarditis	NOUN	O	I-Entity
reported	VERB	O	O
in	ADP	O	O
English	PROPN	O	O
literature	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
symptoms	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
'	PUNCT	O	O
sensitisation	NOUN	O	O
'	PUNCT	O	O
following	VERB	O	O
repeated	VERB	O	O
levodopa	NOUN	O	I-Entity
treatment	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
direct	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
state	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
successfully	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
PTRA	PROPN	O	O
(	PUNCT	O	O
PTRA	PROPN	O	O
group	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
age	NOUN	O	O
70+/-12	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
23	NUM	O	O
female	ADJ	O	O
,	PUNCT	O	O
basal	ADJ	O	O
creatinine	NOUN	O	I-Entity
1.46+/-0.79	NUM	O	O
,	PUNCT	O	O
range	VERB	O	O
0.7	NUM	O	O
-	SYM	O	O
4.9	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
successful	ADJ	O	O
PCI	PROPN	O	O
(	PUNCT	O	O
PCI	PROPN	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
matched	VERB	O	O
for	ADP	O	O
basal	NOUN	O	O
creatinine	NOUN	O	I-Entity
(	PUNCT	O	O
1.44+/-0.6	NUM	O	O
,	PUNCT	O	O
range	VERB	O	O
0.7	NUM	O	O
-	SYM	O	O
3.4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
gender	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

Medical	ADJ	O	O
and	CCONJ	O	O
psychiatric	ADJ	O	O
outcomes	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
transplanted	VERB	O	O
for	ADP	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
of	ADP	O	O
synergy	NOUN	O	O
between	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
novel	NOUN	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
CNSB002	PROPN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
rat	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
and	CCONJ	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
immune	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
was	VERB	O	O
suspected	VERB	O	O
because	ADP	O	O
of	ADP	O	O
positive	ADJ	O	O
direct	ADJ	O	O
antiglobulin	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
negative	ADJ	O	O
eluate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
microspherocytes	NOUN	O	O
on	ADP	O	O
smear	NOUN	O	O
pre-	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
transfusion	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	O
studies	NOUN	O	O
using	VERB	O	O
the	DET	O	O
indirect	ADJ	O	O
antiglobulin	NOUN	O	O
test	NOUN	O	O
were	VERB	O	O
strongly	ADV	O	O
positive	ADJ	O	O
with	ADP	O	O
trimethoprim	NOUN	O	I-Entity
and	CCONJ	O	O
trimethoprim	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
sulfamethoxazole	NOUN	O	I-Entity
but	CCONJ	O	O
negative	ADJ	O	O
with	ADP	O	O
sulfamethoxazole	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
galactose	ADJ	O	I-Entity
concentration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
was	VERB	O	O
several	ADJ	O	O
times	NOUN	O	O
lower	ADJ	O	O
after	ADP	O	O
oral	ADJ	O	O
than	ADP	O	O
after	ADP	O	O
parenteral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
galactose	NOUN	O	I-Entity
dose	NOUN	O	O
.	PUNCT	O	O

